메뉴 건너뛰기




Volumn 3, Issue 11, 2011, Pages

Pharmacogenetics in type 2 diabetes: Potential implications for clinical practice

Author keywords

Genome wide association studies; Metformin; Pharmacogenetics; Single nucleotide polymorphisms; Sulfonylureas; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; CYTOCHROME P450 2C9; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; TROGLITAZONE;

EID: 82255186505     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm292     Document Type: Review
Times cited : (28)

References (77)
  • 1
    • 77950387206 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.
    • Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010, 63:288-295.
    • (2010) J Clin Pathol , vol.63 , pp. 288-295
    • Ford, L.T.1    Berg, J.D.2
  • 8
    • 77953308585 scopus 로고    scopus 로고
    • The long and winding road to warfarin pharmacogenetic testing.
    • Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010, 55:2813-2815.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2813-2815
    • Ginsburg, G.S.1    Voora, D.2
  • 10
  • 14
    • 77955413903 scopus 로고    scopus 로고
    • Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated.
    • Roden DM, Shuldiner AR. Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated. Circulation 2010, 122:445-448.
    • (2010) Circulation , vol.122 , pp. 445-448
    • Roden, D.M.1    Shuldiner, A.R.2
  • 15
    • 0035856943 scopus 로고    scopus 로고
    • Diabetes mellitus and genetically programmed defects in beta-cell function.
    • Bell G, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001, 414:788-791.
    • (2001) Nature , vol.414 , pp. 788-791
    • Bell, G.1    Polonsky, K.S.2
  • 21
    • 78649842241 scopus 로고    scopus 로고
    • Genomics, type 2 diabetes, and obesity.
    • McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010, 363:2339-2350.
    • (2010) N Engl J Med , vol.363 , pp. 2339-2350
    • McCarthy, M.I.1
  • 22
    • 43249125992 scopus 로고    scopus 로고
    • Estimation of the multiple testing burden for genomewide association studies of nearly all common variants.
    • Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008, 32:381-385.
    • (2008) Genet Epidemiol , vol.32 , pp. 381-385
    • Pe'er, I.1    Yelensky, R.2    Altshuler, D.3    Daly, M.J.4
  • 23
    • 78649468820 scopus 로고    scopus 로고
    • The genetics of type 2 diabetes: what have we learned from GWAS?
    • Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS?. Ann N Y Acad Sci 2010, 1212:59-77.
    • (2010) Ann N Y Acad Sci , vol.1212 , pp. 59-77
    • Billings, L.K.1    Florez, J.C.2
  • 24
    • 80051766486 scopus 로고    scopus 로고
    • Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
    • Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011, 12:1161-1191.
    • (2011) Pharmacogenomics , vol.12 , pp. 1161-1191
    • Manolopoulos, V.G.1    Ragia, G.2    Tavridou, A.3
  • 25
    • 0036231580 scopus 로고    scopus 로고
    • Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    • Kirchheiner J, Brockm-Iller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002, 71:286-296.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 286-296
    • Kirchheiner, J.1    Brockm-Iller, J.2    Meineke, I.3    Bauer, S.4    Rohde, W.5    Meisel, C.6    Roots, I.7
  • 28
    • 33646122444 scopus 로고    scopus 로고
    • Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    • Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006, 72:148-154.
    • (2006) Diabetes Res Clin Pract , vol.72 , pp. 148-154
    • Suzuki, K.1    Yanagawa, T.2    Shibasaki, T.3    Kaniwa, N.4    Hasegawa, R.5    Tohkin, M.6
  • 30
    • 0035043009 scopus 로고    scopus 로고
    • Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).
    • Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001, 18:206-212.
    • (2001) Diabet Med , vol.18 , pp. 206-212
    • Gloyn, A.L.1    Hashim, Y.2    Ashcroft, S.J.3    Ashfield, R.4    Wiltshire, S.5    Turner, R.C.6
  • 31
  • 35
    • 70349648967 scopus 로고    scopus 로고
    • Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.
    • Hamming KS, Soliman D, Matemisz LC, Niazi O, Lang Y, Gloyn AL, Light PE. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009, 58:2419-2424.
    • (2009) Diabetes , vol.58 , pp. 2419-2424
    • Hamming, K.S.1    Soliman, D.2    Matemisz, L.C.3    Niazi, O.4    Lang, Y.5    Gloyn, A.L.6    Light, P.E.7
  • 36
    • 33744965950 scopus 로고    scopus 로고
    • The E23K variant of KCNJ11 encoding the pancreatic b-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    • Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P. The E23K variant of KCNJ11 encoding the pancreatic b-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:2334-2339.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 2334-2339
    • Sesti, G.1    Laratta, E.2    Cardellini, M.3    Andreozzi, F.4    Del Guerra, S.5    Irace, C.6    Gnasso, A.7    Grupillo, M.8    Lauro, R.9    Hribal, M.L.10    Perticone, F.11    Marchetti, P.12
  • 37
    • 67949099109 scopus 로고    scopus 로고
    • The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    • Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 2009, 41:387-390.
    • (2009) Horm Metab Res , vol.41 , pp. 387-390
    • Holstein, A.1    Hahn, M.2    Stumvoll, M.3    Kovacs, P.4
  • 38
    • 56149106823 scopus 로고    scopus 로고
    • Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
    • Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, Li X, Sun L, Yang J, Ma W, Wang X, Xu X. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008, 31:1939-1944.
    • (2008) Diabetes Care , vol.31 , pp. 1939-1944
    • Feng, Y.1    Mao, G.2    Ren, X.3    Xing, H.4    Tang, G.5    Li, Q.6    Li, X.7    Sun, L.8    Yang, J.9    Ma, W.10    Wang, X.11    Xu, X.12
  • 46
    • 79951960556 scopus 로고    scopus 로고
    • TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes.
    • Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011, 12:30.
    • (2011) BMC Med Genet , vol.12 , pp. 30
    • Holstein, A.1    Hahn, M.2    Korner, A.3    Stumvoll, M.4    Kovacs, P.5
  • 48
    • 0029099086 scopus 로고
    • Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    • DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
    • (1995) N Engl J Med , vol.333 , pp. 541-549
    • DeFronzo, R.A.1    Goodman, A.M.2
  • 49
    • 0031472452 scopus 로고    scopus 로고
    • Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial.
    • Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997, 103:491-497.
    • (1997) Am J Med , vol.103 , pp. 491-497
    • Garber, A.J.1    Duncan, T.G.2    Goodman, A.M.3    Mills, D.J.4    Rohlf, J.L.5
  • 50
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
    • UKPDS
    • UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UKPDS.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 51
    • 33751159555 scopus 로고    scopus 로고
    • Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
    • Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006, 29:2361-2364.
    • (2006) Diabetes Care , vol.29 , pp. 2361-2364
    • Ong, C.R.1    Molyneaux, L.M.2    Constantino, M.I.3    Twigg, S.M.4    Yue, D.K.5
  • 52
    • 0029133235 scopus 로고
    • Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
    • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:550-554.
    • (1995) N Engl J Med , vol.333 , pp. 550-554
    • Stumvoll, M.1    Nurjhan, N.2    Perriello, G.3    Dailey, G.4    Gerich, J.E.5
  • 54
    • 0037067666 scopus 로고    scopus 로고
    • The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.
    • Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277:25226-25232.
    • (2002) J Biol Chem , vol.277 , pp. 25226-25232
    • Fryer, L.G.D.1    Parbu-Patel, A.2    Carling, D.3
  • 59
    • 67849116869 scopus 로고    scopus 로고
    • Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.
    • Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009, 9:242-247.
    • (2009) Pharmacogenomics J , vol.9 , pp. 242-247
    • Becker, M.L.1    Visser, L.E.2    van Schaik, R.H.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.6
  • 60
    • 62749133967 scopus 로고    scopus 로고
    • Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study.
    • Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes 2009, 58:745-749.
    • (2009) Diabetes , vol.58 , pp. 745-749
    • Becker, M.L.1    Visser, L.E.2    van Schaik, R.H.N.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.C.6
  • 63
    • 18344417084 scopus 로고    scopus 로고
    • Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
    • Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003, 26:825-831.
    • (2003) Diabetes Care , vol.26 , pp. 825-831
    • Bluher, M.1    Lubben, G.2    Paschke, R.3
  • 64
    • 2542443906 scopus 로고    scopus 로고
    • Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
    • Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004, 27:1365-1368.
    • (2004) Diabetes Care , vol.27 , pp. 1365-1368
    • Snitker, S.1    Watanabe, R.M.2    Ani, I.3    Xiang, A.H.4    Marroquin, A.5    Ochoa, C.6    Goico, J.7    Shuldiner, A.R.8    Buchanan, T.A.9
  • 65
    • 34147106645 scopus 로고    scopus 로고
    • Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
    • The Diabetes Prevention Program Research Group
    • Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D, . The Diabetes Prevention Program Research Group Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007, 92:1502-1509. The Diabetes Prevention Program Research Group.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 1502-1509
    • Florez, J.C.1    Jablonski, K.A.2    Sun, M.W.3    Bayley, N.4    Kahn, S.E.5    Shamoon, H.6    Hamman, R.F.7    Knowler, W.C.8    Nathan, D.M.9    Altshuler, D.10
  • 67
    • 23444457610 scopus 로고    scopus 로고
    • Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes.
    • Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, Lim SK, Nam CM, Lee HC. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005, 78:202-208.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 202-208
    • Kang, E.S.1    Park, S.Y.2    Kim, H.J.3    Kim, C.S.4    Ahn, C.W.5    Cha, B.S.6    Lim, S.K.7    Nam, C.M.8    Lee, H.C.9
  • 72
    • 0037116638 scopus 로고    scopus 로고
    • Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
    • Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
    • (2002) JAMA , vol.287 , pp. 360-372
    • Inzucchi, S.E.1
  • 73
    • 19244365650 scopus 로고    scopus 로고
    • Thiazolidinediones.
    • Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
    • (2004) N Engl J Med , vol.351 , pp. 1106-1118
    • Yki-Jarvinen, H.1
  • 74
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 75
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7
  • 76
    • 57349160286 scopus 로고    scopus 로고
    • Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
    • (2009) Diabetologia , vol.52 , pp. 17-30
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.